Detalles de la búsqueda
1.
B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-436620
2.
SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-450959
3.
The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-444076
4.
Hydroxychloroquine pre-exposure prophylaxis to prevent SARS-CoV-2 among health care workers at risk for SARS-CoV-2 exposure: A nonrandomized controlled trial
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22277058
5.
Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430003
6.
Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-463727
7.
Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-452771
8.
Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-474369
9.
Molecularly distinct memory CD4+ T cells are induced by SARS-CoV-2 infection and mRNA vaccination
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-516351
10.
Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21251311
11.
Diversity and selection of SARS-CoV-2 minority variants in the early New York City outbreak
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-442873
12.
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20176651
13.
Hybrid and vaccine-induced immunity against SARS-CoV-2 in MS patients on different disease-modifying therapies
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22276989
14.
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20142570
15.
Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22268752
16.
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21256917
17.
High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-252353
18.
Two-dimensional multiplexed assay for rapid and deep SARS-CoV-2 serology profiling and for machine learning prediction of neutralization capacity
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-454782
19.
Discrete immune response signature to SARS-CoV-2 mRNA vaccination versus infection
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21255677
20.
COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004)
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22276354